Trial Profile
A multicentre, retrospective study to evaluate the efficacy and tolerability of certolizumab pegol in patients with active uveitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2017
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Spondylarthritis; Uveitis
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2017 Results assessing efficacy and tolerability, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 21 Feb 2017 New trial record